Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 32

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 32
---
mbio-specific T cell clones homing into TME (Figure 14); and 

•Treatment-induced increased infiltration T cells into TME with enhanced immune effector signature in responding patients (Figure 15). 

Table 4: Treatment-specific T cell Responses to IO102 (IDO) and/or IO103 (PD-L1) 

    T-win® antigen-specific responseat BASELINE
     
    T-win antigen-specific responseON-TREATMENT

    Response against IO102
     
    10/30 (33.3%)
     
    27/30 (90%)

    Response against IO103
     
    8/30 (26.7%)
     
    25/30 (83.3%)

    Response against IO102 and/or IO103
     
    14/30 (46.7%)
     
    29/30 (96.7%)

29

Figure 14: Increased Frequency of Cylembio®-expanded T cell Clones Detected in TME After Treatment 

Cumulative frequencies of Cylembio-specific TCR rearrangements pre- and post-treatment in one CR patient are shown. 

Figure 15: Treatment-induced Increased Infiltration T cells into TME with Enhanced Immune Effector Signature in Responding Patients 

(A) In a CR patient (PD-L1 negative, LDH high, BRAF WT, M1c), immunohistochemistry (“IHC”) analysis of tumor sections before vs on-treatment revealed more than three-folds increase in infiltrating T cells (left), majority of which were antigen-experienced (positive for PD-1/LAG-3/T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), “Ag+ CD8+”) CD8+ T cells (right). (B) This was accompanied by increased signature of effector T cell activation with concomitant reduction in pro-tumorigenic genes. 

30

MM1636 Cohort B

Ten patients with metastatic melanoma with progressive disease on anti-PD-1 therapy were enrolled from May 2019 to September 2022. A review of patient baseline characteristics for the ten patients with refractory (to an anti PD-1 therapy) melanoma who were included in cohort B of the MM1636 trial shows all patients to have BRAF wild-type tumors, and 50% with available PD-L1 status (n=8) were PD-L1<1%.